NCT05927142View on ClinicalTrials.gov

Combining Anti-PD-L1 Immune Checkpoint Inhibitor Durvalumab With TLR-3 Agonist Rintatolimod in Patients With Metastatic Pancreatic Ductal Adenocarcinoma for Therapy Efficacy

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

January 9, 2024

Primary Completion Date

April 30, 2026

Study Completion Date

April 30, 2027

Conditions
Metastatic Pancreatic Cancer
Interventions
BIOLOGICAL

Durvalumab

Human anti-PD-L1 antibody

DRUG

Rintatolimod

TLR-3 agonist, synthetic double-stranded ribonucleic acid (poly I:C12U)

Trial Locations (1)

3000 CA

RECRUITING

Erasmus MC, Rotterdam

Sponsors
All Listed Sponsors
collaborator

AIM ImmunoTech Inc.

INDUSTRY

collaborator

AstraZeneca

INDUSTRY

lead

Joachim Aerts, MD PhD

OTHER